Browse Category

NASDAQ:DENN News 27 November 2025 - 29 November 2025

Denny’s Closures in Santa Rosa and Canada: What the $620 Million Buyout Really Means for ‘America’s Diner’

Denny’s Closures in Santa Rosa and Canada: What the $620 Million Buyout Really Means for ‘America’s Diner’

As of November 29, 2025, Denny’s is in the middle of one of the biggest shake‑ups in its 72‑year history. The chain has: Here’s how the Santa Rosa and Barrie closures fit into the bigger picture — and what diners, employees and investors should expect next. Santa Rosa’s Coddingtown Denny’s quietly shuts its doors In late November, locals in Santa Rosa woke up to find the Denny’s at Coddingtown Mall on West Steele Lane permanently closed. A sign on the door directs guests to another Denny’s on Baker Avenue, now the only remaining Denny’s in the city.SSBCrack News+1 Coverage pulled
29 November 2025
Denny’s Closes Santa Rosa and Barrie Locations as 150 Restaurants Face Axe After $620 Million Sale

Denny’s Closes Santa Rosa and Barrie Locations as 150 Restaurants Face Axe After $620 Million Sale

Two North American Denny’s closures in Santa Rosa, California and Barrie, Ontario are the latest signs of a historic shake‑up for the 24/7 diner chain as it heads into a $620 million take‑private deal and a year of accelerated restaurant shutdowns. Key points Santa Rosa loses its Coddingtown Mall Denny’s On November 27, 2025, locals in Santa Rosa woke up to find the familiar Denny’s at Coddingtown Mall on West Steele Lane permanently closed. Signs on the doors direct customers to another Denny’s on Baker Avenue, now the only remaining unit in the city. Nearby Petaluma’s Denny’s on Petaluma Boulevard
27 November 2025

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop